Corvus Pharmaceuticals (CRVS) investor relations material

Key program updates and clinical progress

• Lead asset soquelitinib is in a phase III trial for peripheral T-cell lymphoma and advancing in atopic dermatitis (AD) with phase Ib data and a phase II trial planned.

• Phase I AD data showed strong safety, statistical efficacy at 28 days, and a potential remissive effect lasting to day 56.

• Cohort four in AD is testing 200mg b.i.d. for 56 days, with data expected in January; longer treatment may yield greater efficacy.

• Phase II AD trial will be global, enrolling 200 patients across 70 sites, with four arms and a 12-week primary endpoint of EASI reduction.

• Up to 40% of phase II patients may be bio-experienced, and early data suggest efficacy is consistent regardless of prior biologic failure.

Mechanism, biomarkers, and differentiation

• Soquelitinib selectively inhibits ITK, targeting Th2/Th17 pathways, with limited off-target effects and a favorable safety profile.

• Biomarker analysis shows increased Tregs and reduced IL-5, IL-17, IL-31, and TSLP in serum; skin biopsies planned for phase II.

• Small reduction in TARC observed; further biomarker and biopsy data will be reported as available.

• Oral administration and demonstrated safety/efficacy in over 150 patients differentiate the program from mostly injectable competitors.

Commercial opportunity and pipeline expansion

• Each 1% market share in AD is valued at $1 billion, with significant unmet need for safe oral therapies.

• Physicians express interest in a safe oral option for first-line use; only 15% of moderate-severe AD patients use advanced therapies.

• Asthma study planned to start in 2026, targeting another large Th2-driven disease with similar dosing.

• Next-generation ITK inhibitors are in development, 12-15 months from market, aiming for broader patient coverage.

• Partnership in China with Angelini Pharma, which is running a parallel phase II AD trial.